ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY)

Historical Holders from Q1 2014 to Q4 2025

Symbol: ALNY on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 131,516,365
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 129,488,548
Holdings value: $59,035,776,099
% of all portfolios: 0.03%
Number of holders: 809
Number of buys: 493
Number of sells: 270
Average buys %: +0.01%
Average sells %: -0.03%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) based on Schedule 13D/G filings

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
FMR LLC	13%	$7,676,347,201	16,834,095	FMR LLC	30 Sep 2025
VANGUARD GROUP INC	10%	$3,167,662,939	13,056,605	The Vanguard Group	31 Mar 2025
Capital Research Global Investors	5.4%	$1,690,630,939	6,968,513	Capital Research Global Investors	31 Dec 2024

As of 30 Sep 2025 ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 809 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 129,488,548 shares of 131,516,365 outstanding shares and own 98% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) own 76% of the company based on 13F filings as of 30 Sep 2025

Filer	Ownership	Holdings Value	Nb Shares	Share Change %
FMR LLC	13%	$7,646,036,992	16,767,625	+6.1%
Capital World Investors	12%	$7,493,808,123	16,434,253	-2.2%
VANGUARD GROUP INC	10%	$6,185,846,112	13,565,452	+2%
BlackRock, Inc.	7.5%	$4,516,042,243	9,903,601	-0.77%
Capital Research Global Investors	5.5%	$3,293,515,969	7,222,840	+0.43%
JPMORGAN CHASE & CO	3.5%	$2,071,971,357	4,543,770	+120%
STATE STREET CORP	2.3%	$1,405,152,600	3,081,475	-2.9%
BAILLIE GIFFORD & CO	2.1%	$1,271,946,336	2,789,356	-8%
GEODE CAPITAL MANAGEMENT, LLC	1.9%	$1,136,405,944	2,499,242	+4.2%
Dodge & Cox	1.8%	$1,058,480,880	2,321,230	-27%
T. Rowe Price Investment Management, Inc.	1.7%	$991,337,000	2,173,984	-49%
Orbis Allan Gray Ltd	1.5%	$889,638,672	1,950,962	-8%
WELLINGTON MANAGEMENT GROUP LLP	1.4%	$832,802,376	1,826,321	-12%
PRICE T ROWE ASSOCIATES INC /MD/	1.4%	$820,935,000	1,800,294	-43%
AMERICAN CENTURY COMPANIES INC	1.2%	$748,499,727	1,641,441	-8.5%
BANK OF AMERICA CORP /DE/	1.1%	$683,311,896	1,498,491	+19%
Invesco Ltd.	1.1%	$675,719,852	1,481,842	+10%
REGENERON PHARMACEUTICALS, INC.	1.1%	$634,890,168	1,392,303	-69%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	1%	$618,157,704	1,355,609	+699%
JANE STREET GROUP, LLC	0.73%	$437,190,000	958,750	+4095%
TWO SIGMA ADVISERS, LP	0.68%	$406,980,000	892,500	+235%
Legal & General Group Plc	0.68%	$404,827,688	887,780	+1.7%
NORTHERN TRUST CORP	0.63%	$379,916,856	833,151	+0.17%
Qube Research & Technologies Ltd	0.62%	$369,942,768	811,278
AQR CAPITAL MANAGEMENT LLC	0.57%	$336,009,047	744,008	+295%

Institutional Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	3,287	$1,307,294	-$106,204			$397.67	3
2025 Q3	129,488,548	$59,035,776,099	-$785,286,992	$621,709,338	$534,769,985	$456.00	809
2025 Q2	132,062,946	$43,060,444,035	+$1,728,282,756	$178,418,527	$162,891,100	$326.09	645
2025 Q1	126,881,187	$34,233,011,857	-$90,968,751	$204,331,684	$241,096,201	$270.02	615
2024 Q4	127,632,870	$30,037,175,866	-$216,265,374	$152,133,947	$176,466,906	$235.31	587
2024 Q3	123,754,217	$34,035,461,284	+$1,116,635,795	$308,250,279	$336,249,601	$275.03	559
2024 Q2	119,818,858	$29,121,298,158	+$1,425,600,934	$500,482,800	$546,799,100	$243.00	514
2024 Q1	114,506,382	$17,112,788,490	-$462,345,987	$247,936,415	$405,517,470	$149.45	488
2023 Q4	117,037,909	$22,406,153,370	-$144,088,009	$274,539,481	$229,673,255	$191.41	491
2023 Q3	117,774,911	$20,850,702,200	-$144,549,642	$159,372,290	$148,887,970	$177.10	445
2023 Q2	118,559,398	$22,525,153,339	-$212,624,410	$130,155,176	$101,759,146	$189.94	469
2023 Q1	119,657,504	$23,956,079,414	+$6,809,245	$114,389,520	$168,915,720	$200.32	469
2022 Q4	119,654,959	$28,425,215,078	-$3,086,850,614	$173,817,485	$326,031,555	$237.65	477
2022 Q3	133,393,008	$26,709,327,641	+$3,401,526,639	$142,391,976	$253,212,768	$200.16	479
2022 Q2	113,477,846	$16,543,858,767	-$67,066,647	$262,290,785	$422,025,830	$145.85	405
2022 Q1	113,908,234	$18,598,579,814	+$320,228,126	$170,621,484	$120,985,000	$163.29	417
2021 Q4	112,006,374	$18,989,908,067	+$63,928,357	$158,541,236	$204,897,000	$169.58	420
2021 Q3	111,604,687	$21,068,206,424	-$147,043,437	$114,744,202	$262,282,000	$188.81	395
2021 Q2	112,239,402	$19,027,485,774	+$501,915,844	$227,960,400	$264,702,000	$169.52	390
2021 Q1	109,361,699	$15,431,272,628	+$204,818,578	$50,917,000	$82,457,950	$141.19	381
2020 Q4	107,900,409	$14,018,800,907	-$114,208,967	$117,040,091	$123,583,568	$129.97	353
2020 Q3	108,499,178	$15,789,451,789	-$460,283,345	$124,305,000	$124,325,000	$145.60	347
2020 Q2	111,562,100	$16,522,566,788	+$489,977,680	$111,645,000	$125,489,000	$148.11	363
2020 Q1	108,370,173	$11,796,531,647	+$294,735,312	$118,192,000	$134,835,000	$108.85	317
2019 Q4	105,328,965	$12,129,387,603	-$233,499,979	$110,696,000	$128,573,000	$115.17	306
2019 Q3	108,059,417	$8,689,910,646	+$177,605,607	$65,643,000	$99,390,000	$80.42	276
2019 Q2	106,070,864	$7,694,654,472	+$800,559,176	$52,489,000	$55,704,000	$72.56	283
2019 Q1	96,763,330	$9,041,659,322	+$427,442,108	$43,764,000	$76,367,000	$93.45	279
2018 Q4	92,434,388	$6,736,307,943	+$108,054,744	$47,844,000	$113,479,000	$72.91	274
2018 Q3	90,577,162	$7,927,334,207	-$105,883,718	$92,320,000	$119,797,000	$87.52	297
2018 Q2	91,541,386	$9,015,538,809	-$37,011,096	$44,400,000	$84,780,000	$98.49	303
2018 Q1	91,623,594	$10,912,571,096	-$75,880,031	$89,621,000	$102,691,000	$119.10	285
2017 Q4	92,127,969	$11,704,641,437	+$613,133,919	$116,224,000	$148,077,000	$127.05	275
2017 Q3	87,490,797	$10,279,386,005	+$76,555,680	$263,177,000	$306,133,000	$117.49	228
2017 Q2	87,236,413	$6,951,381,175	+$478,024,217	$54,617,000	$72,632,000	$79.76	221
2017 Q1	82,296,913	$4,218,075,181	+$357,641,470	$27,080,000	$33,364,000	$51.25	191
2016 Q4	79,901,866	$2,991,766,834	-$16,232,332	$26,833,000	$27,792,000	$37.44	203
2016 Q3	77,521,060	$5,253,109,562	+$213,492,546	$26,241,000	$46,865,000	$67.78	250
2016 Q2	74,050,576	$4,109,046,677	+$155,696,020	$22,074,000	$57,722,000	$55.49	240
2016 Q1	70,923,645	$4,451,021,161	+$295,037,172	$45,525,000	$49,867,000	$62.77	248
2015 Q4	66,039,006	$6,216,981,299	+$73,218,963	$22,132,000	$18,006,000	$94.14	258
2015 Q3	65,414,849	$5,256,534,541	-$57,051,793	$30,235,000	$31,812,000	$80.36	254
2015 Q2	65,565,499	$7,859,319,459	+$143,389,344	$43,513,000	$35,836,000	$119.87	274
2015 Q1	64,472,950	$6,731,323,619	+$672,355,194	$56,081,000	$42,890,000	$104.42	236
2014 Q4	57,984,886	$5,624,460,197	-$127,912,074	$16,306,000	$31,000,000	$97.00	214
2014 Q3	58,977,372	$4,606,139,951	+$102,404,978	$46,641,000	$44,959,000	$78.10	184
2014 Q2	57,779,618	$3,648,879,764	+$120,117,247	$32,675,000	$34,755,000	$63.17	190
2014 Q1	55,704,223	$3,739,161,613	+$8,742,143	$54,373,000	$25,321,000	$67.14	193